The endocannabinoid system has emerged as a major target for addressing inflammatory dysregulation, including neuroinflammatory and hypersensitivity is- sues. Cannabidiol (CBD) has been shown in both laboratory and clinical settings to be an incredibly effective tool in autism protocols through its effects in calming neural and immune activation, as well as the autonomic nervous system. However, low, variable, and slow absorption rates make it difficult to predict the efficacy of any dosage.
Speaker: Christopher Shade, PhD
Christopher Shade, PhD, is the founder and CEO of Quicksilver Scientific®, a nanoparticle dietary supplement company located in Louisville, Colorado. Dr. Shade’s background is deeply rooted in the biological, environmental, and analytical chemistry of mercury in all its forms and their interactions with sulfur compounds, particularly glutathione and its enzyme system making him an expert in heavy metals toxicity and detoxification. He has patented a mercury speciation diagnostic process to analyze human toxicity, founded the only clinical lab in the world offering mercury speciation analysis, and has designed cutting-edge dietary supplements and protocols for detoxification, immune and foundational wellness, and longevity using Quicksilver Delivery Systems® technology. This patent-pending nanoparticle delivery technology supports the bioavailability of difficult to absorb compounds for higher efficacy. Dr. Shade is regularly sought out to speak as an educator on the topics of mercury, environmental toxicities, the human detoxification system, longevity, immune health, and the functional applications of dietary supplements in the U.S. and internationally.
